APL engages in independent thinking to pursue unorthodox and complex investment opportunities, aiming to add enduring value to the assets in its portfolio.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Elizabeth Buck

Alexander Flohr

Alexander Mayweg

David M. Epstein

Black Diamond Therapeutics, Inc.

Farmers Guide provides news and insights related to farming in the UK, self-described as a leading monthly farming magazine.

Farmers Guide

Workstream provides payroll solutions designed for hourly workers.

Metric
Company Name	APL	Black Diamond Therapeutics, Inc.	Farmers Guide	Workstream
Symbol		BDTX
MSH ID	COM:APLGROUP	COM:BLACKDIAMONDTHERAPEUTICS	UK:CO:FARMERSGUIDE	US:WORKSTREAM
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Healthcare	Commercial & Professional Services	Commercial & Professional Services
Industry	Investment Management	Biotechnology	Agriculture	Human Resources
Country	US	US	GB	US
Stage				Series B
Employee Count		54
Website	aplgroup.com	blackdiamondtherapeutics.com	farmersguide.co.uk	workstream.us
LinkedIn		black-diamond-therapeutics	farmers-guide
Founders

Metric
Market Cap	288.58M
Enterprise Value
Monthly Web Traffic		70.32K	2.69M
Web Traffic Growth		0.34	0.31
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:APLGROUP

APL

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue